ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial - a podcast by European Society of Cardiology
from 2019-09-02T10:44:49
::
::
With Roxana Mehran, The Mount Sinai Hospital - USA, Jan Steffel, University Hospital Zurich - Switzerland & Diana Gorog, University of Hertfordshire - UK
Link to paper: https://bit.ly/2lz0NfG
Further episodes of ESC Cardio Talk
Further podcasts by European Society of Cardiology
Website of European Society of Cardiology